10 steps to secure investment as a life science scale up

Yogan Patel.png

Unlocking the potential of your groundbreaking life science business begins with securing the funding needed to propel your innovation to new heights. 

In this comprehensive guide, Yogan Patel, Partner, and Head of Life Sciences at MHA, unveils a ten-step roadmap for preparing to pitch for funding. Each step represents a critical milestone on your journey towards acquiring the financial resources that will enable you to drive innovation, make a positive impact on healthcare, and transform your vision into a thriving reality.

Whether you're a biotech startup on the cusp of a medical breakthrough or a molecular diagnostics company looking to expand your operations, the path to funding success demands careful planning and precise execution. From refining your value proposition and developing a compelling narrative that resonates with potential investors to conducting rigorous market research and assembling a rock-solid financial plan, this infographic equips you with the knowledge and strategies needed to make your pitch stand out in a crowded funding landscape.

The life science sector is known for its unique challenges, and this roadmap is designed to help you navigate them with confidence and precision.

10 essential steps for building investor-ready documents

Biotech funding: 10 steps to secure investment as a life science scale up

Market Research

Your research is likely to have been leading edge and the result of years of collective work between you and your fellow researchers. It is essential that you can showcase the potential of your work with evidence led approach that ideally will already have included some peer assessment, notwithstanding the need to protect your IP.

Business plan

Prepare a comprehensive business plan that outlines your vision, mission, target market, competitive analysis, marketing strategy and financial projections. Investors will want to see that you have a clear plan for commercialisation. This is possibly the toughest stage as comparative metrics may be difficult to build, attempt to breakdown the market and segment it by example using geography, patient type/outcome and the cost of existing therapies as a benchmark.

Investment proposal/Pitch Deck

Create a compelling investment proposal or pitch deck that presents you and your team as a strong proposition. This needs to be in a concise and professionally produced format; detailed information should be on hand but not in the slide deck or it becomes difficult to track in the context of a pitch presentation. Include key highlights about your therapy, the problem it addresses, how it works, clinical trial results (if any), your business model including matters such as outsourcing and manufacturing if appropriate, revenue projections and the amount of investment you are seeking.

Regulatory and clinical trial documentation

Your product could be facing stringent regulatory requirements. Prepare documentation related to the regulatory approvals you have obtained or are pursuing. If you have already conducted pre-clinical trials, include relevant data and results to demonstrate safety and efficacy.

Intellectual Property (IP)

Perhaps this is an obvious point, but investors will want to know about the intellectual property protecting your therapy or technology. Provide information on patents and any other forms of IP you have secured or have pending. If you don’t have this, be prepared to demonstrate how this will be managed with expert opinions to support your points.

Team and advisory support

You and your team are a big part of the investment, after all, there is likely to be no revenue, so it’s down to you, your team, and the IP. Highlight the expertise of your management team and key personnel involved in the project to date. Investors will want to know that you have a capable and experienced team to drive the business forward. Ideally, you will already have advisors or the equivalent in the form of non-executives with appropriate sector expertise, you can mention their involvement as a form of endorsement. You may also wish to include other advisors including accountants and lawyers who may have supported the development of your business or pitch.

Financial plan

You will need detailed financial statements and plans for your business, including profit and loss statements, balance sheets and cash flow statements. You will also need to take a medium-term view on how you see the business developing, so present your financial projections for the next 3-5 years, showing how the investment should be uitilised and the potential return on investment.

Managing risks

Be transparent about the risks involved in your business and IP; to some extent you may be navigating uncharted waters given that you are likely breaking new ground and research. Discuss how you might plan to mitigate the risks, whether these are around the product, key staff or the market and customers. Investors appreciate a thorough understanding of the potential challenges and how you plan to navigate them as this gives them the opportunity to structure their investment or indeed introduce new co-investment partners.

Securing regulatory approval and payment

Depending on where you intend to market your product or therapy, you will need to think about your plans for regulatory approval and how you intend to secure reimbursement once the product or therapy is on the market. Investors will want to see that you have quantified the cost of treatment where appropriate and that it is likely to secure approval from the prevailing regulatory authority.

Market engagement

Give some consideration to your business development strategy and the balance of marketing and sales activity. You will need to articulate your strategy for reaching your target market and building a customer base. It will also be essential to demonstrate how you intend managing the ‘mark access’ process of engaging with physicians, patients, and key opinion leaders; whether you budget for this in-house or outsource it, you will need to be clear on the resources for this and timelines.


More news and updates 

CEO Update - 8 July 2024

It is a fantastic way to start the week with news of Europe’s largest Series A biotech spin-out this year from the UK. Congratulations to Myricx Bio, an Imperial College London and Francis Crick Institute spin-out company focusing on a novel class of payloads for antibody-drug conjugates (ADCs), for announcing their Series A financing of £90 million.

Brandon Capital's vision for a transcontinental life science axis

Jonathan Tobin, Partner at Brandon Capital, discusses the firm's recent close of its sixth fund at A$270 million, bringing its total assets under management to over A$1.25 billion. He also explores how Brandon Capital is strategically connecting Australia, New Zealand, the UK, and the US.

PIR International interview with Anja Harmeier, CEO, Rewind Therapeutics

In this blog, PIR International presents an interview with Anja Harmeier, CEO of Rewind Therapeutics, as part of their BioLeader interview series.

CEO Update - 1 July 2024

I will watch the General Election this Thursday with great interest, like the rest of the country, and update you on the new ministers and members of Parliament next week. You can access the policy backgrounds of the main parties and view our webinar on what the campaign has taught us about what our sector should expect from the new parliament and government.

Shaping future leaders in biomanufacturing: insights from MAC LeaP

Over the past nine years, Dr Tony Bradshaw, Managing Director of Biosocius, has collected data from three distinct projects within the biotechnology sector. This effort has yielded unique and valuable insights that can help professionals thrive and build sustainable, fulfilling careers. By analysing behavioural profiles and consulting with industry experts, we can better understand the evolving demands of leadership in bioscience.

Why digital matters for neurodegeneration treatments

Molly Andrews of the UK Dementia Research Institute, Priya Kalia of SciTribe, and Miranda Weston-Smith of BioBeat highlight the urgent need for innovative digital solutions and investments in the accurate diagnosis and effective treatment of neurodegenerative diseases, as emphasised at BioBeat24.

CEO Update - 24 June 2024

In two Newscasts time, we will know the outcome of the UK General Election to be held on Thursday, 4 July. Join our webinar tomorrow at 1 pm where we will discuss what we have learned from the campaigns and manifestoes about potential future policies and people important for our sector after the result.

CEO Update - 17 June 2024

Last week saw the key parties launch their general election manifestoes. This week sees a set piece hosting debate with the core parties talking about their approach to science and innovation at a live hustings at the Royal Society.

Life sciences in the public eye: what can we learn from the manifestoes?  

With fewer than twenty days to go and the manifestoes of the main parties now published, the BIA policy team pick apart what each party is pledging for the life science sector.

The evolving life sciences landscape

The life sciences sector in the UK has been the subject of significant attention over recent years. Activity in the sector has been spurred on by a multitude of drivers and its potential has also been frequently highlighted by the UK government.


More within